Limits...
The 9L(LUC)/Wistar rat glioma model is not suitable for immunotherapy.

Yang L, Zhao J, Zhou G, Wang Y, Li L, Yuan H, Nan X, Guan L, Pei X - Neural Regen Res (2012)

Bottom Line: The availability of a well-characterized animal brain tumor model will play an important role in identifying treatments for human brain tumors.Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9L(LUC)/F344 model.However, many infiltrating CD4- and CD8-positive cells were observed within the tumors of the 9L(LUC)/Wistar model.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, the 263 Hospital, Beijing 101149, China ; Department of Neurology, South West Hospital, the Third Military Medical University of Chinese PLA, Chongqing 400038, China.

ABSTRACT
The availability of a well-characterized animal brain tumor model will play an important role in identifying treatments for human brain tumors. Wistar rats bearing 9L glioma cells can develop solid, well-circumcised tumors, and may be a useful animal model for the evaluation of various therapeutic approaches for gliosarcomas. In this study, the 9L/Wistar rat glioma model was produced by intracerebral implantation of 9L(LUC) glioma cells syngenic to Fischer 344 (F344) rats. Bioluminescence imaging showed that tumors progressively grew from day 7 to day 21 in 9L(LUC)/F344 rats, and tumor regression was found in some 9L(LUC)/Wistar rats. Hematoxylin-eosin staining verified that intracranial tumors were gliomas. Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9L(LUC)/F344 model. However, many infiltrating CD4- and CD8-positive cells were observed within the tumors of the 9L(LUC)/Wistar model. Our data suggests that compared with 9L/F344 rats, 9L glioma Wistar rats may not be suitable for evaluating brain glioma immunotherapies, even though the model induced an immune response and exhibited tumor regression.

No MeSH data available.


Related in: MedlinePlus

Tumor growth was detected by bioluminescence imaging in vivo.9LLUC cells were implanted intracerebrally into Fischer 344 or Wistar rats (n=4 per group).Tumor growth in F344 rats is presented (A-D) from day 7 to day 21 after cell implantation. No continued growth of tumors in Wistar rats receiving simultaneous intracranial injections of 9LLUC (105) from day 7 to day 21 was observed (E-H), while globular brain tumor growth occurred constantly after implantation in 9L/Wistar rats (I–L) receiving 106 9LLUC cells, without evidence of regression.Right scale is used for photon counting, and tumor size, and tumor cell number are calculated according to the right scale and colors.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4308791&req=5

Figure 2: Tumor growth was detected by bioluminescence imaging in vivo.9LLUC cells were implanted intracerebrally into Fischer 344 or Wistar rats (n=4 per group).Tumor growth in F344 rats is presented (A-D) from day 7 to day 21 after cell implantation. No continued growth of tumors in Wistar rats receiving simultaneous intracranial injections of 9LLUC (105) from day 7 to day 21 was observed (E-H), while globular brain tumor growth occurred constantly after implantation in 9L/Wistar rats (I–L) receiving 106 9LLUC cells, without evidence of regression.Right scale is used for photon counting, and tumor size, and tumor cell number are calculated according to the right scale and colors.

Mentions: 9LLUC glioma cells were injected into the cranium of Wistar or F344 rats to monitor tumor growth. Tumor growth was measured at the beginning on day 0 and weekly thereafter using bioluminescence imaging. By day 7, all animals showed successful tumor development following bioluminescence imaging. Tumor growth after intracranial injection of 9LLUC cells at varying doses into the right caudate nucleus of Wistar or F344 rats is shown in Figure 2. All 9LLUC/F344 rats yielded tumors with an injection of 105 cells (Figures 2A–D); in contrast, Wistar rats injected with 106 cells showed successful tumor development (Figures 2I-L), yet Wistar rats injected with 105 cells developed tumors only on day 7 and regressed thereafter (Figures 2E-H). Compared with 9L/Fischer rats, Wistar rats implanted with 9L glioma cells (106) showed a significant (P < 0.01) increase in photon counts at day 7, however, there was no difference in photon counts between 9L/Fischer rats and Wistar rats at day 21 (P > 0.05; Figure 3).


The 9L(LUC)/Wistar rat glioma model is not suitable for immunotherapy.

Yang L, Zhao J, Zhou G, Wang Y, Li L, Yuan H, Nan X, Guan L, Pei X - Neural Regen Res (2012)

Tumor growth was detected by bioluminescence imaging in vivo.9LLUC cells were implanted intracerebrally into Fischer 344 or Wistar rats (n=4 per group).Tumor growth in F344 rats is presented (A-D) from day 7 to day 21 after cell implantation. No continued growth of tumors in Wistar rats receiving simultaneous intracranial injections of 9LLUC (105) from day 7 to day 21 was observed (E-H), while globular brain tumor growth occurred constantly after implantation in 9L/Wistar rats (I–L) receiving 106 9LLUC cells, without evidence of regression.Right scale is used for photon counting, and tumor size, and tumor cell number are calculated according to the right scale and colors.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4308791&req=5

Figure 2: Tumor growth was detected by bioluminescence imaging in vivo.9LLUC cells were implanted intracerebrally into Fischer 344 or Wistar rats (n=4 per group).Tumor growth in F344 rats is presented (A-D) from day 7 to day 21 after cell implantation. No continued growth of tumors in Wistar rats receiving simultaneous intracranial injections of 9LLUC (105) from day 7 to day 21 was observed (E-H), while globular brain tumor growth occurred constantly after implantation in 9L/Wistar rats (I–L) receiving 106 9LLUC cells, without evidence of regression.Right scale is used for photon counting, and tumor size, and tumor cell number are calculated according to the right scale and colors.
Mentions: 9LLUC glioma cells were injected into the cranium of Wistar or F344 rats to monitor tumor growth. Tumor growth was measured at the beginning on day 0 and weekly thereafter using bioluminescence imaging. By day 7, all animals showed successful tumor development following bioluminescence imaging. Tumor growth after intracranial injection of 9LLUC cells at varying doses into the right caudate nucleus of Wistar or F344 rats is shown in Figure 2. All 9LLUC/F344 rats yielded tumors with an injection of 105 cells (Figures 2A–D); in contrast, Wistar rats injected with 106 cells showed successful tumor development (Figures 2I-L), yet Wistar rats injected with 105 cells developed tumors only on day 7 and regressed thereafter (Figures 2E-H). Compared with 9L/Fischer rats, Wistar rats implanted with 9L glioma cells (106) showed a significant (P < 0.01) increase in photon counts at day 7, however, there was no difference in photon counts between 9L/Fischer rats and Wistar rats at day 21 (P > 0.05; Figure 3).

Bottom Line: The availability of a well-characterized animal brain tumor model will play an important role in identifying treatments for human brain tumors.Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9L(LUC)/F344 model.However, many infiltrating CD4- and CD8-positive cells were observed within the tumors of the 9L(LUC)/Wistar model.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, the 263 Hospital, Beijing 101149, China ; Department of Neurology, South West Hospital, the Third Military Medical University of Chinese PLA, Chongqing 400038, China.

ABSTRACT
The availability of a well-characterized animal brain tumor model will play an important role in identifying treatments for human brain tumors. Wistar rats bearing 9L glioma cells can develop solid, well-circumcised tumors, and may be a useful animal model for the evaluation of various therapeutic approaches for gliosarcomas. In this study, the 9L/Wistar rat glioma model was produced by intracerebral implantation of 9L(LUC) glioma cells syngenic to Fischer 344 (F344) rats. Bioluminescence imaging showed that tumors progressively grew from day 7 to day 21 in 9L(LUC)/F344 rats, and tumor regression was found in some 9L(LUC)/Wistar rats. Hematoxylin-eosin staining verified that intracranial tumors were gliomas. Immunohistochemistry results demonstrated that no CD4- and CD8-positive cells were found in the syngeneic 9L(LUC)/F344 model. However, many infiltrating CD4- and CD8-positive cells were observed within the tumors of the 9L(LUC)/Wistar model. Our data suggests that compared with 9L/F344 rats, 9L glioma Wistar rats may not be suitable for evaluating brain glioma immunotherapies, even though the model induced an immune response and exhibited tumor regression.

No MeSH data available.


Related in: MedlinePlus